Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of clinical & cellular immunology

• Publication date

  2015-04-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4172/2155-9899.1000322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenic peptide discovery in cancer genomes.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer

  2014cited by this paper
• Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

  2014cited by this paper
• Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

  2014cited by this paper
• HLA-Binding Properties of Tumor Neoepitopes in Humans

  2014cited by this paper
• Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

  2014cited by this paper
• Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

  2014influential reference
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

  2014cited by this paper
• Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes

  2014cited by this paper
• Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

  2014influential reference
• Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

  2014influential reference
• High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

  2014cited by this paper
• Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions

  2014influential reference
• Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014influential reference
• Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell–Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4

  2014cited by this paper
• Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens

  2014influential reference
• Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

  2014cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Cancer Immunology at the Crossroads : Functional Genomics Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells

  2013cited by this paper
• Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

  2013cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013cited by this paper
• Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer

  2013cited by this paper
• Lessons from the cancer genome.

  2013cited by this paper
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

  2013cited by this paper
• Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

  2013cited by this paper
• Hepatotoxicity with combination of vemurafenib and ipilimumab.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Immunotherapy at Large: The road to personalized cancer vaccines

  2013cited by this paper
• Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.

  2013cited by this paper
• Therapeutic cancer vaccines: current status and moving forward.

  2012cited by this paper
• Exploiting the mutanome for tumor vaccination.

  2012influential reference
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies

  2012cited by this paper
• Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting

  2012cited by this paper
• An immune-active tumor microenvironment favors clinical response to ipilimumab

  2012cited by this paper
• Expression of tumour-specific antigens underlies cancer immunoediting

  2011cited by this paper
• Machine learning competition in immunology - Prediction of HLA class I binding peptides.

  2011cited by this paper
• Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras

  2011cited by this paper
• A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

  2011cited by this paper
• T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Identification of CD8+ T Cell Epitopes in the West Nile Virus Polyprotein by Reverse-Immunology Using NetCTL

  2010cited by this paper
• The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

  2009cited by this paper
• Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

  2009cited by this paper
• Epitope landscape in breast and colorectal cancer.

  2008cited by this paper
• High-throughput oncogene mutation profiling in human cancer

  2007influential reference
• The Genomic Landscapes of Human Breast and Colorectal Cancers

  2007cited by this paper
• Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach.

  2006cited by this paper
• Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.

  2005cited by this paper
• Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy

  2005cited by this paper
• The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.

  2005cited by this paper
• T Cells Associated with Tumor Regression Recognize Frameshifted Products of the CDKN2A Tumor Suppressor Gene Locus and a Mutated HLA Class I Gene Product

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.

  2004cited by this paper
• Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

  2001cited by this paper
• the Identification of Tumor-reactive T-Cell Epitopes Use of Two Predictive Algorithms of the World Wide Web for Updated

  2000cited by this paper
• Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

  1995cited by this paper

• Analysis of thymic generation of shared T‐cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild‐type antigens

  2023cites this paper
• Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer

  2023cites this paper
• Transcriptional configurations of myeloproliferative neoplasms.

  2022cites this paper
• Pretraining Transformers for TCR-pMHC Binding Prediction

  2022cites this paper
• Automated protein-protein structure prediction of the T cell receptor-peptide major histocompatibility complex

  2022cites this paper
• NeoSplice: a bioinformatics method for prediction of splice variant neoantigens

  2022cites this paper
• Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

  2021cites this paper
• Deep learning-based prediction of the T cell receptor–antigen binding specificity

  2021cites this paper
• Novel frontiers in detecting cancer metastasis

  2018cites this paper
• The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis

  2018cites this paper
• Composite Analysis of Immunological and Metabolic Markers Defines Novel Subtypes of Triple Negative Breast Cancer

  2017cites this paper
• Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

  2017cites this paper
• Assessment of combined vaccination and immune modulation as an anti-tumour therapy

  2016cites this paper
• Biology and its Significance

  2015cites this paper
• A Spotted View of Cancer

  2015cites this paper
• Antibody Therapeutics : Challenges , Strategies and Innovations for the Next Generation

  year unknowncites this paper